Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.
AbbVie’s Orilissa snagged its first FDA approval over the summer, and now it’s looking to make it two.
With I-O drug development continually changing, an understanding of clinical biomarker testing is needed now more than ever.
New phase 3b data showed that, with just eight weeks of treatment, Mavyret could cure HCV patients with compensated cirrhosis.
Just one day after Novartis laid out plans for its Alcon spinoff, it found itself fending off a rumor that it also intends to wave goodbye to Sandoz.
The FDA has handed Lilly’s Emgality a 'breakthrough' nod in cluster headaches. Lilly plans to file for approval in that use by the end of the year.
Management at Dr. Reddy’s oncology drug plant isn’t getting the FDA's message. A recent inspection found five of eight observations were repeats.
After losses and mistrials this year in its talc defense, Johnson & Johnson has scored a second straight win in a mesothelioma case in California.
Merck kicked off a rolling FDA submission for its Ebola vaccine that's already been deployed against outbreaks in the Democratic Republic of Congo.
Pfizer launched its third biosim, Retacrit, at a significant discount to anemia drugs from Amgen and Johnson & Johnson.
Korean securities watchdog has requested to review whether the company should be delisted and recommended the dismissal of its CEO.
